ADMA Biologics, Inc.
ADMA
$9.37
-$0.17-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.53% | 68.48% | -55.87% | 1.45% | 6.72% |
| Total Depreciation and Amortization | -13.46% | -6.60% | 5.25% | 4.28% | 0.54% |
| Total Amortization of Deferred Charges | 20.00% | 0.53% | -10.05% | -32.54% | -29.52% |
| Total Other Non-Cash Items | -20.81% | -79.45% | 108.43% | 280.55% | 172.43% |
| Change in Net Operating Assets | 28.89% | 116.29% | -264.10% | -130.03% | -371.24% |
| Cash from Operations | 39.74% | 396.06% | -29.03% | -46.89% | -53.69% |
| Capital Expenditure | 6.85% | 45.91% | 60.68% | -1,260.61% | -17.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -178.95% | 11,442.86% | 100.00% | 64.88% |
| Cash from Investing | 10.72% | 150.93% | 89.96% | -1,208.56% | -6.85% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 98.44% | -- | 98.44% | -151.56% | -- |
| Issuance of Common Stock | -98.30% | 482.18% | -2.93% | -93.16% | 523.56% |
| Repurchase of Common Stock | -2,333.42% | -1,771.18% | -1,307.76% | -1,972.71% | -71.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 98.42% | -- | -- |
| Cash from Financing | -61,383.33% | -42.14% | 70.61% | -9.26% | 113.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -111.43% | 260.28% | 59.64% | -1,780.29% | -56.52% |